Medivir and CRT to develop novel ADAM8 inhibitors for cancer
This article was originally published in Scrip
Executive Summary
Sweden's Medivir and Cancer Research Technology (CRT), the charity Cancer Research UK's commercialization and development arm, are partnering to develop a new class of drugs targeting the cell surface protein ADAM8, which may have promise in the treatment of pancreatic cancer, among other tumor types.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.